Keros Therapeutics, Inc. (KROS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Keros Therapeutics, Inc. on November 22, 2022. The report serves as a Regulation FD disclosure regarding upcoming investor relations activities.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on event disclosure rather than financial performance.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces scheduled conference presentations.
Guidance, Outlook, and Management Commentary
Management has scheduled the following events for the Company's President and Chief Executive Officer, Jasbir Seehra:
- Piper Sandler 34th Annual Healthcare Conference: Tuesday, November 29, 2022, at 10:00 a.m. Eastern time.
- 5th Annual Evercore ISI HealthCONx Conference: Thursday, December 1, 2022, at 8:50 a.m. Eastern time.
The press release detailing these events is included as Exhibit 99.1. The filing explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the date and time of the upcoming fireside chats at the Piper Sandler and Evercore ISI conferences.
- Review the full text of the press release (Exhibit 99.1) for any additional commentary not summarized in the 8-K.
- Note that this filing contains no new financial data; investors should refer to the most recent 10-Q or 10-K for financial metrics.